The European Medicines Agency will review Ariad's Iclusig at its December meeting, according to a meeting agenda posted to the regulator's website. Ariad shares are up 9.8% to $4.24 following circulation of the agenda.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.